Dr. Pavol Cekan (CEO & co-founder of MultiplexDX International) was invited by the Startup Grind community in Bratislava to discuss ideas about upcoming technologies and new trends in the healthcare industry. Daniel Coulton Shaw, a healthcare entrepreneur and international clinic ambassador, moderated the session. Pavol and Daniel engaged in a thought-provoking and interactive debate about revolutionizing the healthcare industry. Pavol spoke about his scientific background and transformation from a scientist to businessman as well as MutiplexDX and the challenges of crowdfunding. He described the situation of the healthcare system in Slovakia from the view of cancer diagnostics and treatment and expressed his vision and ideas for improvement.
Outlining the corner-stone of his plan, Dr. Pavol Cekan said:
“A proactive and willing patient becomes a centerpiece of the healthcare system and is actively involved in getting better health care, precise diagnostics and personalized treatment.”
Startup Grind is a global startup platform created to educate, inspire, and connect entrepreneurs all around the world. It nurtures startup ecosystems in many countries through events, media, and partnerships with organizations like Google for Startups. The center-core of their activities are monthly events featuring successful local founders, innovators, educators and investors who share their inspiring stories and encourage attendees to build their own successful businesses. The idea of Startup Grind started by Derek Andersen and Spencer Nielsen in February 2010 in a small office in Silicon Valley. The original goal was to bring together friends who would help each other to build their businesses, make
synergies, connect with strategic partners, and secure funding.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.